Newsletter

Pol. Merkur. Lek (Pol. Med. J.), 2016, XL/235: 040-045 Maximize

Pol. Merkur. Lek (Pol. Med. J.), 2016, XL/235: 040-045

Title: Biochemical predictors of anthracyclin and trastuzumab induced cardiotoxicity in early diagnostics of cardiomyopathy

Authors: Słowik A, Lelakowska-Pieła M, Konduracka E. 

More details

09/235

40,00 zł

SUMMARY IN POLISH & ENGLISH. FULL ARTICLE ONLY IN POLISH.

Biochemical predictors of anthracyclin and trastuzumab induced cardiotoxicity in early diagnostics of cardiomyopathy


Słowik A1, Lelakowska-Pieła M2, Konduracka E2.

Jagiellonian University Medical College, Krakow, Poland: 1Oncology Department; 2Coronary Disease and Heart Failure Department

The treatment based on athracyclines and trastuzumab may lead to heart failure in oncological setting. Assessment of the heart function is conducted using radiological examinations, especially echocardiography. Biochemical diagnostics enables to depict clinically silent cardiac dysfunction at an earlier stage. Biomarkers that showed to be the most promising in predicting the development of deterioration of systolic and/or diastolic function in course of chemotherapy are troponins and NT-pro-BNP. However, no cut-off point had been yet determined, especially in terms of cardiotoxicity induced by oncological therapy. Biomarkers serum level may be dependent on many conditions, mostly comorbidities, what makes the interpretation of the results difficult. Trials involving mikro RNA particles, which depict the molecular level of the pathological changes, also those involved in the development of cardiomyopathy, are underway.

Key words: anthracyclines; trastuzumab; cardiotoxicity; biomarkers

Pol Med J, 2016; XL (235); 40–45